메뉴 건너뛰기




Volumn 37, Issue 2, 2014, Pages 277-287

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENZYME ANTIBODY; GALSULFASE; GLYCOSAMINOGLYCAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

EID: 84921735523     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-013-9654-7     Document Type: Article
Times cited : (28)

References (25)
  • 1
    • 84879684477 scopus 로고    scopus 로고
    • Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme(R)) therapy
    • 3590402 22669363 10.1007/s10545-012-9481-2
    • Braunlin E, Rosenfeld H, Kampmann C et al (2013) Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis 36:385-394
    • (2013) J Inherit Metab Dis , vol.36 , pp. 385-394
    • Braunlin, E.1    Rosenfeld, H.2    Kampmann, C.3
  • 2
    • 0030658865 scopus 로고    scopus 로고
    • Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI
    • 9356736 10.1016/S8756-3282(97)00175-0
    • Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K, Fazzalari NL (1997) Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 21:425-431
    • (1997) Bone , vol.21 , pp. 425-431
    • Byers, S.1    Nuttall, J.D.2    Crawley, A.C.3    Hopwood, J.J.4    Smith, K.5    Fazzalari, N.L.6
  • 3
    • 0031029536 scopus 로고    scopus 로고
    • Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI
    • 507847 9045867 10.1172/JCI119208
    • Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ (1997) Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 99:651-662
    • (1997) J Clin Invest , vol.99 , pp. 651-662
    • Crawley, A.C.1    Niedzielski, K.H.2    Isaac, E.L.3    Davey, R.C.4    Byers, S.5    Hopwood, J.J.6
  • 4
    • 77954629021 scopus 로고    scopus 로고
    • Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
    • 2904323 20634905
    • Decker C, Yu ZF, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3:89-100
    • (2010) J Pediatr Rehabil Med , vol.3 , pp. 89-100
    • Decker, C.1    Yu, Z.F.2    Giugliani, R.3
  • 5
    • 0026580312 scopus 로고
    • The Denver II: A major revision and restandardization of the Denver Developmental Screening Test
    • 1370185
    • Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B (1992) The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 89:91-97
    • (1992) Pediatrics , vol.89 , pp. 91-97
    • Frankenburg, W.K.1    Dodds, J.2    Archer, P.3    Shapiro, H.4    Bresnick, B.5
  • 6
    • 82255179466 scopus 로고    scopus 로고
    • Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI
    • 21930407 10.1016/j.ymgme.2011.08.029
    • Furujo M, Kubo T, Kosuga M, Okuyama T (2011) Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 104:597-602
    • (2011) Mol Genet Metab , vol.104 , pp. 597-602
    • Furujo, M.1    Kubo, T.2    Kosuga, M.3    Okuyama, T.4
  • 7
    • 0034633090 scopus 로고    scopus 로고
    • Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses
    • 11179586 10.1016/S0188-4409(00)00104-1
    • Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martinez SE et al (2000) Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 31:505-510
    • (2000) Arch Med Res , vol.31 , pp. 505-510
    • Gallegos-Arreola, M.P.1    Machorro-Lazo, M.V.2    Flores-Martinez, S.E.3
  • 8
    • 34547682071 scopus 로고    scopus 로고
    • Management guidelines for mucopolysaccharidosis VI
    • 17671068 10.1542/peds.2006-2184
    • Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405-418
    • (2007) Pediatrics , vol.120 , pp. 405-418
    • Giugliani, R.1    Harmatz, P.2    Wraith, J.E.3
  • 9
    • 27744493202 scopus 로고    scopus 로고
    • Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase
    • 15930196 10.1542/peds.2004-1023
    • Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681-e689
    • (2005) Pediatrics , vol.115
    • Harmatz, P.1    Ketteridge, D.2    Giugliani, R.3
  • 10
    • 33744978567 scopus 로고    scopus 로고
    • Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
    • 16647419 10.1016/j.jpeds.2005.12.014
    • Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533-539
    • (2006) J Pediatr , vol.148 , pp. 533-539
    • Harmatz, P.1    Giugliani, R.2    Schwartz, I.3
  • 11
    • 46949093352 scopus 로고    scopus 로고
    • Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
    • 18502162 10.1016/j.ymgme.2008.04.001
    • Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469-475
    • (2008) Mol Genet Metab , vol.94 , pp. 469-475
    • Harmatz, P.1    Giugliani, R.2    Schwartz, I.V.3
  • 12
    • 84879688261 scopus 로고    scopus 로고
    • Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)
    • 22127392 10.1007/s10545-011-9410-9
    • Hendriksz CJ, Giugliani R, Harmatz P et al (2013) Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 36:373-384
    • (2013) J Inherit Metab Dis , vol.36 , pp. 373-384
    • Hendriksz, C.J.1    Giugliani, R.2    Harmatz, P.3
  • 13
    • 2642573491 scopus 로고    scopus 로고
    • Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation
    • 15346915 10.1007/s00431-004-1428-7
    • Heron D, Baumann C, Benichou JJ, Harpey JP, Le Merrer M (2004) Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur J Pediatr 163:323-326
    • (2004) Eur J Pediatr , vol.163 , pp. 323-326
    • Heron, D.1    Baumann, C.2    Benichou, J.J.3    Harpey, J.P.4    Le Merrer, M.5
  • 14
    • 84876092083 scopus 로고    scopus 로고
    • Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI
    • 23535281 10.1016/j.ymgme.2013.02.014
    • Horovitz DD, Magalhaes TS, Acosta A et al (2013) Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 109:62-69
    • (2013) Mol Genet Metab , vol.109 , pp. 62-69
    • Horovitz, D.D.1    Magalhaes, T.S.2    Acosta, A.3
  • 15
    • 0036311539 scopus 로고    scopus 로고
    • A common metric for the Griffiths Scales
    • 1719193 12138056 10.1136/adc.87.2.109
    • Ivens J, Martin N (2002) A common metric for the Griffiths Scales. Arch Dis Child 87:109-110
    • (2002) Arch Dis Child , vol.87 , pp. 109-110
    • Ivens, J.1    Martin, N.2
  • 17
    • 70349555987 scopus 로고    scopus 로고
    • 2000 CDC Growth Charts for the United States: Methods and development
    • Kuczmarski RJ, Ogden CL, Guo SS et al (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11:1-190
    • (2002) Vital Health Stat , vol.11 , pp. 1-190
    • Kuczmarski, R.J.1    Ogden, C.L.2    Guo, S.S.3
  • 19
    • 77953049350 scopus 로고    scopus 로고
    • Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study
    • 19968667 10.1111/j.1399-0004.2009.01324.x
    • McGill JJ, Inwood AC, Coman DJ et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 77:492-498
    • (2010) Clin Genet , vol.77 , pp. 492-498
    • McGill, J.J.1    Inwood, A.C.2    Coman, D.J.3
  • 20
    • 43049096056 scopus 로고    scopus 로고
    • Growth charts for patients affected with Morquio A disease
    • 18412124 10.1002/ajmg.a.32281
    • Montano AM, Tomatsu S, Brusius A, Smith M, Orii T (2008) Growth charts for patients affected with Morquio A disease. Am J Med Genet A 146A:1286-1295
    • (2008) Am J Med Genet A , vol.146 , pp. 1286-1295
    • Montano, A.M.1    Tomatsu, S.2    Brusius, A.3    Smith, M.4    Orii, T.5
  • 21
    • 20144386995 scopus 로고    scopus 로고
    • Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
    • 15690405 10.1002/ajmg.a.30579
    • Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 134A:144-150
    • (2005) Am J Med Genet A , vol.134 , pp. 144-150
    • Swiedler, S.J.1    Beck, M.2    Bajbouj, M.3
  • 22
    • 84867884581 scopus 로고    scopus 로고
    • Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: A case series
    • 22441840 10.1007/s10545-012-9474-1
    • Thumler A, Miebach E, Lampe C et al (2012) Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis 35:1071-1079
    • (2012) J Inherit Metab Dis , vol.35 , pp. 1071-1079
    • Thumler, A.1    Miebach, E.2    Lampe, C.3
  • 24
    • 0024520993 scopus 로고
    • Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion
    • 2493341
    • Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP (1989) Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 35:374-379
    • (1989) Clin Chem , vol.35 , pp. 374-379
    • Whitley, C.B.1    Ridnour, M.D.2    Draper, K.A.3    Dutton, C.M.4    Neglia, J.P.5
  • 25
    • 84860194402 scopus 로고    scopus 로고
    • Expert recommendations for the laboratory diagnosis of MPS VI
    • 22405600 10.1016/j.ymgme.2012.02.005
    • Wood T, Bodamer OA, Burin MG et al (2012) Expert recommendations for the laboratory diagnosis of MPS VI. Mol Genet Metab 106:73-82
    • (2012) Mol Genet Metab , vol.106 , pp. 73-82
    • Wood, T.1    Bodamer, O.A.2    Burin, M.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.